PARIN5, a Novel Thrombin Receptor Antagonist Modulates a Streptozotocin Mice Model for Diabetic Encephalopathy.

Int J Mol Sci · 2023 · PMC9917200 · PMID 36768341

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

of borderline significanceno p-value reported

Evaluating PARIN5 was a secondary outcome, and although PARIN5 treatment resulted in no significant difference between treated animals and healthy control in many of the evaluated parameters, it was of borderline significance when comparing PARIN5 treated to untreated STZ diabetic mice.

also in 2,624 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.